Paper40802193
Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.
Yamaguchi J and 12 others. JAMA Cardiol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial. Papers, record 40802193. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40802193
- Disease
- coronary artery disorder241 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02642419 | Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study | Derived from the trial | Yes |
Source ClinicalTrials.gov
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35936042 | Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. | J Arrhythm | 2022 | https://conductscience.org/library/papers/35936042 | PubMed |
| 2 | 34736731 | Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial. | JACC Cardiovasc Interv | 2021 | https://conductscience.org/library/papers/34736731 | PubMed |
| 3 | 24550531 | Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. | Circ Cardiovasc Interv | 2014 | https://conductscience.org/library/papers/24550531 | PubMed |
| 4 | 27959713 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959713 | PubMed |
| 5 | 31492505 | Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. | Lancet | 2019 | https://conductscience.org/library/papers/31492505 | PubMed |
| 6 | 16765759 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. | Lancet | 2006 | https://conductscience.org/library/papers/16765759 | PubMed |
| 7 | 9834303 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. | N Engl J Med | 1998 | https://conductscience.org/library/papers/9834303 | PubMed |
| 8 | 22813718 | Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. | Drug Metab Pharmacokinet | 2013 | https://conductscience.org/library/papers/22813718 | PubMed |
| 9 | 39918465 | Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials. | J Am Coll Cardiol | 2025 | https://conductscience.org/library/papers/39918465 | PubMed |
| 10 | 31475793 | Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31475793 | PubMed |
| 11 | 21830957 | Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21830957 | PubMed |
| 12 | 15842354 | Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. | J Thromb Haemost | 2005 | https://conductscience.org/library/papers/15842354 | PubMed |
| 13 | 31116032 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. | Circulation | 2019 | https://conductscience.org/library/papers/31116032 | PubMed |
| 14 | 31272556 | Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. | J Am Coll Cardiol | 2019 | https://conductscience.org/library/papers/31272556 | PubMed |
| 15 | 32865374 | Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32865374 | PubMed |
| 16 | 26314532 | Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. | J Am Coll Cardiol | 2015 | https://conductscience.org/library/papers/26314532 | PubMed |
| 17 | 32173684 | JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. | Circ J | 2020 | https://conductscience.org/library/papers/32173684 | PubMed |
| 18 | 31623473 | Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. | Expert Opin Drug Saf | 2019 | https://conductscience.org/library/papers/31623473 | PubMed |
| 19 | 12644343 | Oral anticoagulants in patients with coronary artery disease. | J Am Coll Cardiol | 2003 | https://conductscience.org/library/papers/12644343 | PubMed |
| 20 | 38033089 | 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | Circulation | 2024 | https://conductscience.org/library/papers/38033089 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| RIVAROXABAN | CHEMBL198362 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL198362 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40802193
GET https://conductscience.org/api/papers/v1/40802193/references?page=2